Literature DB >> 20195151

Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study.

Umberto Veronesi1, Giuseppe Viale, Giovanni Paganelli, Stefano Zurrida, Alberto Luini, Viviana Galimberti, Paolo Veronesi, Mattia Intra, Patrick Maisonneuve, Francesca Zucca, Giovanna Gatti, Giovanni Mazzarol, Concetta De Cicco, Dario Vezzoli.   

Abstract

OBJECTIVE: Sentinel node biopsy (SNB) is widely used to stage the axilla in breast cancer. We present 10-year follow-up of our single-institute trial designed to compare outcomes in patients who received no axillary dissection if the sentinel node was negative, with patients who received complete axillary dissection.
METHODS: From March 1998 to December 1999, 516 patients with primary breast cancer up to 2 cm in pathologic diameter were randomized either to SNB plus complete axillary dissection (AD arm) or to SNB with axillary dissection only if the sentinel node contained metastases (SN arm).
RESULTS: The 2 arms were well-balanced for number of sentinel nodes found, proportion of positive sentinel nodes, and all other tumor and patient characteristics. About 8 patients in the AD arm had false-negative SNs on histologic analysis: a similar number (8, 95% CI: 3-15) of patients with axillary involvement was expected in SN arm patients who did not receive axillary dissection; but only 2 cases of overt axillary metastasis occurred. There were 23 breast cancer-related events in the SN arm and 26 in the AD arm (log-rank, P = 0.52), while overall survival was greater in the SN arm (log-rank, P = 0.15).
CONCLUSIONS: Preservation of healthy lymph nodes may have beneficial consequences. Axillary dissection should not be performed in breast cancer patients without first examining the sentinel node.

Entities:  

Mesh:

Year:  2010        PMID: 20195151     DOI: 10.1097/SLA.0b013e3181c0e92a

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  125 in total

1.  Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance).

Authors:  Judy C Boughey; Vera J Suman; Elizabeth A Mittendorf; Gretchen M Ahrendt; Lee G Wilke; Bret Taback; A Marilyn Leitch; Teresa S Flippo-Morton; Henry M Kuerer; Monet Bowling; Kelly K Hunt
Journal:  Ann Surg       Date:  2015-03       Impact factor: 12.969

2.  Outcome of sentinel lymph node biopsy in breast cancer using dye alone: a single center review with a median follow-up of 5 years.

Authors:  Yoshinari Ogawa; Katsumi Ikeda; Kana Ogisawa; Shinya Tokunaga; Hiroko Fukushima; Takeshi Inoue; Yoshihiro Mori; Akiko Tachimori; Toru Inoue; Yukio Nishiguchi
Journal:  Surg Today       Date:  2013-09-26       Impact factor: 2.549

3.  Prevalence and Consequences of Axillary Lymph Node Dissection in the Era of Sentinel Lymph Node Biopsy for Breast Cancer.

Authors:  Tina W F Yen; Purushottam W Laud; Liliana E Pezzin; Emily L McGinley; Erica Wozniak; Rodney Sparapani; Ann B Nattinger
Journal:  Med Care       Date:  2018-01       Impact factor: 2.983

4.  Minimal Invasive and Individualizing Management of the Axillary Nodes.

Authors:  Jun Won Min; Jihyoung Cho
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  Regional Disease Control in Selected Patients with Sentinel Lymph Node Involvement and Omission of Axillary Lymph Node Dissection.

Authors:  Gábor Cserni; Róbert Maráz
Journal:  Pathol Oncol Res       Date:  2015-02-04       Impact factor: 3.201

6.  Do the ACOSOG Z0011 Criteria Affect the Number of Sentinel Lymph Nodes Removed?

Authors:  Preeti Subhedar; Michelle Stempel; Anne Eaton; Monica Morrow; Mary L Gemignani
Journal:  Ann Surg Oncol       Date:  2015-07-16       Impact factor: 5.344

Review 7.  New concepts in axillary management of breast cancer.

Authors:  Can Atalay
Journal:  World J Clin Oncol       Date:  2014-12-10

8.  Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial.

Authors:  Viviana Galimberti; Bernard F Cole; Stefano Zurrida; Giuseppe Viale; Alberto Luini; Paolo Veronesi; Paola Baratella; Camelia Chifu; Manuela Sargenti; Mattia Intra; Oreste Gentilini; Mauro G Mastropasqua; Giovanni Mazzarol; Samuele Massarut; Jean-Rémi Garbay; Janez Zgajnar; Hanne Galatius; Angelo Recalcati; David Littlejohn; Monika Bamert; Marco Colleoni; Karen N Price; Meredith M Regan; Aron Goldhirsch; Alan S Coates; Richard D Gelber; Umberto Veronesi
Journal:  Lancet Oncol       Date:  2013-03-11       Impact factor: 41.316

9.  Late Axillary Recurrence After Negative Sentinel Lymph Node Biopsy is Uncommon.

Authors:  Cindy Matsen; Kristine Villegas; Anne Eaton; Michelle Stempel; Aidan Manning; Hiram S Cody; Monica Morrow; Alexandra Heerdt
Journal:  Ann Surg Oncol       Date:  2016-03-08       Impact factor: 5.344

10.  Automating tumor classification with pixel-by-pixel contrast-enhanced ultrasound perfusion kinetics.

Authors:  Casey N Ta; Yuko Kono; Christopher V Barback; Robert F Mattrey; Andrew C Kummel
Journal:  J Vac Sci Technol B Nanotechnol Microelectron       Date:  2012-03-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.